Beijing Abace Biology Co., Ltd. v. Zhang

122 F.4th 448
CourtCourt of Appeals for the First Circuit
DecidedDecember 2, 2024
Docket24-1424
StatusPublished
Cited by1 cases

This text of 122 F.4th 448 (Beijing Abace Biology Co., Ltd. v. Zhang) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Beijing Abace Biology Co., Ltd. v. Zhang, 122 F.4th 448 (1st Cir. 2024).

Opinion

United States Court of Appeals For the First Circuit

No. 24-1424

BEIJING ABACE BIOLOGY CO., LTD.,

Plaintiff, Appellant,

v.

CHUNHONG ZHANG and MTOZ BIOLABS, INC.,

Defendants, Appellees.

APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

[Hon. Indira Talwani, U.S. District Judge]

Before

Rikelman, Selya, and Kayatta, Circuit Judges.

Willard C. Shih, with whom Stephen T. Melnick, Littler Mendelson, P.C., and Wilentz, Goldman & Spitzer P.A. were on brief, for appellant. Zackary L. Stillings, with whom Yuanyou Sunny Yang and Frost Brown Todd, LLP were on brief, for appellees.

December 2, 2024 SELYA, Circuit Judge. Plaintiff-appellant Beijing Abace

Biology Co., Ltd. (Abace) challenges the district court's entry of

summary judgment in favor of defendants-appellees Dr. Chunhong

Zhang (Dr. Zhang) and MtoZ Biolabs, Inc. (MtoZ). Discerning no

error, we affirm.

I

We rehearse the relevant facts and travel of the case.

In that endeavor, we "scrutinize the record in the light most

favorable to the summary judgment loser and draw all reasonable

inferences therefrom to that party's behoof." All. of Auto. Mfrs.

v. Gwadosky, 430 F.3d 30, 34 (1st Cir. 2005).

Abace and Creative Dynamics, Inc. (Creative Dynamics)

are affiliated companies that provide research and development

resources in the life sciences and pharmaceutical spaces. Both

companies were founded in 2004. Abace is headquartered in Beijing

and Creative Dynamics is headquartered in New York. Although the

precise nature of the corporate relationship between Abace and

Creative Dynamics is murky, the record suggests that the two firms

have a "contract" relationship and that some corporate officers

work for both companies.1

In December of 2014, Abace hired Dr. Zhang. She became

a "supplier" in its creative proteomics department. As such, Dr.

1 We need not probe this too deeply as only Abace — and not Creative Dynamics — is a party to this appeal.

- 2 - Zhang was required to "find the product or service" requested by

"go[ing] online, like Google or Baidu [a Chinese search engine],

and search[ing] which company can provide this [product or service]

and then call[ing] them to ask them for the price and how long

they can deliver this [product or service] and then giv[ing] the

supplier's price back to [sic] sales person." While working for

Abace, Dr. Zhang was stationed in China.

During her tenure with Abace, Dr. Zhang signed several

employment-related agreements. These included two so-called

Cadres Agreements, dated January 9, 2016, and November 2, 2016,

respectively.2 The agreements are the same in all aspects relevant

to this decision. Separate and apart from the Cadres Agreements,

the record reflects that the parties entered into a Confidentiality

and Non-Competition Agreement (the Non-Compete Agreement) and a

Labor Contract, both dated November 2, 2016.

Each of the Cadres Agreements stated that it "appli[ed]

to all current employees of Creative Dynamics and CD Biosciences

(CD Inc), i.e., all current employees of the Company." We assume

— favorably to Abace — that Dr. Zhang fell within the reach of

those agreements.

2 Although these are called the "Creative Dynamics Cadres Agreements," the signatories are Abace and Dr. Zhang. This discrepancy is unexplained, but it is not material to the resolution of this appeal.

- 3 - Those agreements also defined certain terms. As

relevant here, those agreements defined "senior cadre[s]" as "the

first and second level leaders of each Division," meaning the

"primary and secondary head of each Division." Additionally, they

defined "senior executive[s]" as those persons who "[e]xercise the

right of operation and management" and who have certain powers

over personnel. What is more, the January Cadres Agreement stated

that, "[w]ithin 2 years from the date of termination of senior

executives, they shall not hold a position or hold a part-time job

in an organization with similar business and competitive

relationship with the Company."

On May 1, 2017, Dr. Zhang's employment with Abace was

terminated, and she signed an employment separation certificate.

This certificate referred to the obligations in the Non-Compete

Agreement.

In September of 2017, Dr. Zhang co-founded MtoZ, a

company headquartered in Massachusetts. MtoZ provides proteomics,

metabolomics, bioinformatics, and biopharmaceutical analysis

services to researchers. See About Us, MtoZ-Biolabs,

https://www.mtoz-biolabs.com/about-us.html

[https://perma.cc/5SJQ-4NCF].

Abace responded to this initiative by filing an action

against Dr. Zhang and MtoZ in the United States District Court for

- 4 - the District of Massachusetts.3 In the operative pleading (the

second amended complaint), it claimed that Dr. Zhang had breached

both her contract with Abace and her fiduciary duty to Abace; that

MtoZ had tortiously interfered with Abace's business and business

relationships; and that Dr. Zhang and MtoZ were liable for unjust

enrichment.4 After pretrial discovery was completed, all parties

moved for summary judgment. The district court granted summary

judgment in favor of Dr. Zhang and MtoZ. See Creative Dynamics,

Inc. v. Zhang, No. 20-11711, 2024 WL 1375941 (D. Mass. Mar. 31,

2024). This timely appeal followed.

II

Summary judgment is appropriate when "the movant shows

that there is no genuine dispute as to any material fact and the

movant is entitled to judgment as a matter of law." Fed. R. Civ.

P. 56(a). A dispute is genuine if "the evidence about the fact is

such that a reasonable jury could resolve the point in favor of

the nonmoving party." Rivera-Muriente v. Agosto-Alicea, 959 F.2d

349, 352 (1st Cir. 1992) (quoting United States v. Plat 20, Lot

17, Great Harbor Neck, 960 F.2d 200, 204 (1st Cir. 1992)). A fact

3 There were additional parties below (including Creative Dynamics, as a plaintiff). None of these parties is a party to this appeal. 4 Simultaneously, Abace sought relief against Dr. Zhang in

China in both arbitration and court proceedings. Neither of those proceedings is still pending, and we make no further mention of them.

- 5 - is material if it could affect the outcome of the case. See Baker

v. St. Paul Travelers Ins. Co., 670 F.3d 119, 125 (1st Cir. 2012).

"The summary judgment ritual is standard fare: once the movant

'adumbrate[s] an absence of evidence to support the nonmoving

party's case,' . . . the burden shifts to the nonmovant to

establish the existence of a genuine issue of material fact."

Boykin v. Genzyme Therapeutic Prods., LP, 93 F.4th 56, 60 (1st

Cir. 2024) (alteration in original) (quoting Brennan v. Hendrigan,

888 F.2d 189, 191 (1st Cir. 1989)).

We review the district court's grant of summary judgment

de novo. See Spencer v. Roche, 659 F.3d 142

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
122 F.4th 448, Counsel Stack Legal Research, https://law.counselstack.com/opinion/beijing-abace-biology-co-ltd-v-zhang-ca1-2024.